Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies
Roehrborn CG and Siegel RL (1996) Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. Urology 48: 406-415
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial
Roehrborn CG (2001) Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 58: 953-959
Long-term sustained improvement in symptoms of benign prostatic hyperplasia with dual 5-α reductase inhibitor dutasteride: Results of 4-year studies
Roehrborn CG et al. (2005) Long-term sustained improvement in symptoms of benign prostatic hyperplasia with dual 5-α reductase inhibitor dutasteride: Results of 4-year studies. BJU Int 96: 572-577
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
McConnell JD et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338: 557-563
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group
Lepor H et al. (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 335: 533-539
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial
Kirby RS et al. (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61: 119-126
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
McConnell JD et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387-2398
α-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-α-reductase inhibitor dutasteride
Barkin J et al. (2003) α-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-α-reductase inhibitor dutasteride. Eur Urol 44: 461-466
An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases
Evans CP et al. (2005) An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU Int 95: 743-749
